

UCLA

UCLA Previously Published Works

Title

Effectiveness of a Peer Navigation Intervention to Sustain Viral Suppression Among HIV-Positive Men and Transgender Women Released From Jail: The LINK LA Randomized Clinical Trial

Permalink

<https://escholarship.org/uc/item/3n95095k>

Journal

JAMA Internal Medicine, 178(4)

ISSN

2168-6106

Authors

Cunningham, William E

Weiss, Robert E

Nakazono, Terry

et al.

Publication Date

2018-04-01

DOI

10.1001/jamainternmed.2018.0150

Peer reviewed

JAMA Internal Medicine | [Original Investigation](#)

# Effectiveness of a Peer Navigation Intervention to Sustain Viral Suppression Among HIV-Positive Men and Transgender Women Released From Jail

## The LINK LA Randomized Clinical Trial

William E. Cunningham, MD, MPH; Robert E. Weiss, PhD; Terry Nakazono, MS; Mark A. Malek, MD; Steve J. Shoptaw, PhD; Susan L. Ettner, PhD; Nina T. Harawa, PhD

**IMPORTANCE** Diagnosis of human immunodeficiency virus (HIV) infection, linkage and retention in care, and adherence to antiretroviral therapy are steps in the care continuum enabling consistent viral suppression for people living with HIV, extending longevity and preventing further transmission. While incarcerated, people living with HIV receive antiretroviral therapy and achieve viral suppression more consistently than after they are released. No interventions have shown sustained viral suppression after jail release.

**OBJECTIVE** To test the effect on viral suppression in released inmates of the manualized LINK LA (Linking Inmates to Care in Los Angeles) peer navigation intervention compared with standard transitional case management controls.

**DESIGN, SETTING, AND PARTICIPANTS** Randomized clinical trial conducted from December 2012 through October 2016 with people living with HIV being released from Los Angeles (LA) County Jail. All participants were (1) 18 years or older; (2) either men or transgender women diagnosed with HIV; (3) English speaking; (4) selected for the transitional case management program prior to enrollment; (5) residing in LA County; and (6) eligible for antiretroviral therapy.

**MAIN OUTCOMES AND MEASURES** Change in HIV viral suppression (<75 copies/mL) over a 12-month period.

**INTERVENTIONS** During the 12-session, 24-week LINK LA Peer Navigation intervention, trained peer navigators counseled participants on goal setting and problem solving around barriers to HIV care and adherence, starting while the participants were still in jail. After their release, they continued counseling while they accompanied participants to 2 HIV care visits, then facilitated communication with clinicians during visits.

**RESULTS** Of 356 participants randomized, 151 (42%) were black; 110 (31%) were Latino; 303 (85%) were men; 53 (15%) were transgender women; and the mean (SD) age was 39.5 (10.4) years. At 12 months, viral suppression was achieved by 62 (49.6%) of 125 participants in the peer navigation (intervention) arm compared with 45 (36.0%) of 125 in the transitional case management (control) arm, for an unadjusted treatment difference of 13.6% (95% CI, 1.34%-25.9%;  $P = .03$ ). In the repeated measures, random effects, logistic model the adjusted probability of viral suppression declined from 52% at baseline to 30% among controls, while those in the peer navigation arm maintained viral suppression at 49% from baseline to 12 months, for a difference-in-difference of 22% (95% CI, 0.03-0.41;  $P = .02$ ).

**CONCLUSIONS AND RELEVANCE** The LINK LA peer navigation intervention was successful at preventing declines in viral suppression, typically seen after release from incarceration, compared with standard transitional case management. Future research should examine ways to strengthen the intervention to increase viral suppression above baseline levels.

**TRIAL REGISTRATION** [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01406626) Identifier: NCT01406626

JAMA Intern Med. doi:10.1001/jamainternmed.2018.0150  
Published online March 12, 2018.

[← Invited Commentary](#)

[+ Supplemental content](#)

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** William E. Cunningham, MD, MPH, University of California, Los Angeles, 911 Broxton Ave, Los Angeles, CA 90024 ([wcunningham@mednet.ucla.edu](mailto:wcunningham@mednet.ucla.edu)).

The human immunodeficiency virus (HIV) care continuum has emerged as the leading paradigm for controlling the HIV epidemic, as linkage to care, retention in care, and viral suppression have both individual and public health benefits.<sup>1-3</sup> Approximately 1 in 7 HIV-positive persons pass through US corrections annually,<sup>4</sup> and HIV prevalence among incarcerated persons is 3 to 5 times that of the general population.<sup>5,6</sup> While incarcerated, people living with HIV experience highly structured environments and access to health care, including antiretroviral therapy.<sup>7</sup> They often achieve viral suppression while incarcerated despite lacking HIV care before entry.<sup>8-10</sup> After release from incarceration, many fail to link to care soon enough or long enough to sustain viral suppression.<sup>9,11,12</sup> An observational study found that only 30% had filled antiretroviral prescriptions 60 days after release from Texas prisons.<sup>13</sup> A recent randomized clinical trial of a multi-component intervention among HIV-positive persons leaving 2 southern state prisons showed no improvement in viral suppression at 6 months after release.<sup>14</sup> There are no known randomized trials of any interventions shown to sustain viral suppression over 12 months after jail release.

We conducted a randomized clinical trial called Linking Inmates to Care in LA (Los Angeles) (or “LINK LA”), a peer navigation intervention among HIV-positive men and transgender women released from a large municipal jail system to evaluate its effects on viral suppression. The trial protocol from the application for funding is provided in [Supplement 1](#). The concept of *peer navigation* is rooted in *patient navigation*—the direct assistance provided to help low-income, vulnerable patients find their way through complex health care systems to obtain timely diagnosis and treatment.<sup>15-17</sup> While *patient navigators* may include professionals such as case managers,<sup>18</sup> we adopted a model in which *peer navigators* were strictly lay staff members, who could be considered peers of the participants, to promote trust with this often stigmatized population.<sup>19,20</sup>

In designing LINK LA, we hypothesized that peer navigation would improve viral suppression compared with transitional case management over 12 months. We also hypothesized that the intervention would be more effective among nonusers of substances (opiates, stimulants, and binge alcohol) than among users.

## Methods

### Setting

This study was conducted from December 2012 through October 2016 among inmates being released from LA County Jail, the largest jail system in the United States. With an estimated 62 000 people living with HIV, LA County is the second largest epicenter of the US epidemic after New York City.<sup>21,22</sup> The study was approved by the University of California, Los Angeles Institutional Review Board, and all participants provided their written informed consent.

### Study Design

LINK LA was a 2-group randomized trial: the intervention group participated in a 12-session, 24-week peer navigation

## Key Points

**Question** What is the effect of a peer navigation intervention on viral suppression of human immunodeficiency virus (HIV) among people living with HIV released from jail?

**Findings** In the LINK LA randomized clinical trial of peer navigation that included 356 men and transgender women leaving Los Angeles County Jail, the adjusted probability of viral suppression among controls declined from 52% at baseline to 30%, while the LINK LA intervention group maintained viral suppression at 49% from baseline to 12 months, for a significant difference-in-difference of 22%.

**Meaning** The LINK LA peer navigation intervention prevented the declines in viral suppression observed in standard care and typically seen after release from incarceration.

intervention, while the control group followed the standard transitional case management protocol. The study had a preplanned target sample size of 356 participants. Assuming 30% attrition, and a final sample of 250 participants at 12 months (125 per arm), in simulations we had 80% power ( $\alpha = .05$ ) to detect a minimal difference of 17% viral suppression between arms when controls had 50% viral suppression, and a 15% minimal difference when controls had 30% viral suppression.


### Eligibility and Participant Flow

Routinely, inmates were screened at intake and referred for medical and transitional case management services if they tested positive for HIV. All participants were (1) 18 years or older; (2) either men or transgender women diagnosed with HIV; (3) English speaking; (4) selected for the transitional case management program prior to enrollment; (5) residing in LA County; and (6) eligible for antiretroviral therapy<sup>23</sup> or incarcerated while undergoing antiretroviral therapy. Exclusion criteria were (1) inability to give informed consent; (2) planned transfer to prison; and/or (3) a stay in jail of less than 5 days. Of 465 potentially eligible persons, 105 ultimately were not eligible, and 4 declined. The final sample included 356 participants (**Figure**). All 180 participants randomized to the peer navigation intervention completed the first session in jail; 91% completed at least the first 2 didactic intervention sessions ( $n = 163$ ); 83% completed at least 1 of the 2 accompaniment sessions to medical care ( $n = 150$ ); and 59% completed all 12 sessions of LINK LA ( $n = 106$ ), including 2 accompaniments (**Figure**).

### Enrollment, Randomization, and Blinding

After recruitment, staff members obtained written informed consent and conducted the baseline interview. Then, using sequentially numbered envelopes, we randomized the participants in a 1:1 ratio to the peer navigation intervention or transitional case management control group using computer-generated, randomly permuted blocks of 4 and 6 to prevent anticipation of assignment to study condition. To prevent contamination, peer navigators interacted with participants only in the intervention arm and did not share intervention materials with controls. We provided basic cell phones with text

Figure. Study Enrollment and Progress Flowchart for the LINK LA Trial



functions to all participants to arrange data collection, promote study retention, and facilitate intervention activities.

### Peer Navigation Intervention

We developed the manualized LINK LA peer navigation intervention using a conceptual model adapted from social cognitive theory, as applied to the continuum of HIV care.<sup>24,25</sup> We trained lay peer navigators to act as role models who could walk participants through the continuum steps: (1) linkage or reengagement, (2) retention, and (3) antiretroviral therapy adherence. The peer navigation intervention addresses social-environmental factors by promoting social support<sup>26</sup> and trusting relationships with peer navigators and clinicians.<sup>27</sup> LINK LA teaches skills to overcome social stigma<sup>28</sup> and discrimination<sup>29</sup> and to facilitate access to care<sup>30,31</sup> through appointment scheduling, reminders, transportation assistance, accompaniment to medical and other health care appointments, and assistance with meeting competing subsistence

needs.<sup>32</sup> The intervention addresses personal factors by emphasizing the importance of retention in care and antiretroviral therapy adherence and advancing the knowledge and skills necessary for engaging these activities. The intervention supports behavioral factors related to HIV care and adherence by promoting self-efficacy, positive health expectations, and goal-setting and problem-solving behaviors.<sup>24,25</sup>

Before the participants were released from jail, peer navigators delivered the intervention content during 1- to 2-hour sessions in person in a private conference room. After the participants were released, the navigators conducted the sessions in community settings. They initiated relationships with participants before they left jail, met them at the time of release, held sessions in private community settings, then counseled and modeled retention and adherence behaviors during accompaniment to 2 scheduled HIV medical care appointments up to 24 weeks after release. Navigators imparted the manualized content in conversational format in each

session (eTable 1 in Supplement 2). During accompaniment, navigators prepared participants for clinician visits, then helped answer questions, took notes during the visit, and facilitated recommendations following visits.

### Peer Navigator Selection, Training, and Supervision

Peer navigators were either black or Latino (1 black woman, 1 Latina woman, 1 Latino man, and 2 black men) and were selected for having experiences in common with incarcerated people living with HIV (such as prior incarceration, being a patient retained in HIV care, and/or prior substance abuse recovery). Peer navigators completed a comprehensive, 1-week training regimen prior to field work, using a detailed manual of operations. To address fidelity, navigators received daily monitoring, weekly supervision, and periodic auditing of records. Navigators completed a checklist documenting delivery of each session. We also held unannounced field visits to observe select intervention sessions to assure fidelity. We rated intervention fidelity on a 3-point scale with 1 representing high and 3, low fidelity. We found a mean (SD) overall fidelity rating of 1.6 (0.8).

### Control Intervention

The control arm was the standard of care, which is transitional case management. All known people living with HIV in LA County Jail received transitional case management needs assessments. Transitional case management arm participants also received referrals for postrelease housing, substance abuse treatment, and HIV care from case managers. Peer navigators provided these referrals to peer navigator arm participants.

### Data Collection

We conducted face-to-face interviews at baseline before release, and at 3, 6, and 12 months after release. At baseline, we collected electronic medical record data on HIV viral load. At months 3 and 12, we collected blood samples for viral load and analyzed it using RealTime HIV-1 assays (Abbott Laboratories). Participants were paid \$25 for participation in the baseline interview, \$50 each for 3- and 6-month interviews, and \$75 for 12-month interviews plus blood samples.

### Outcome Measures

The prespecified primary outcome was viral suppression, defined as undetectable viral load (<75 copies/mL). We supplemented viral load testing with data from the LA County Department of Public Health Casewatch system<sup>33</sup> whenever interviewed participants were not available for testing when due. Casewatch maintains electronic record data for Ryan White-funded clinics where most (n = 313) of the participants were seen after their release. Blinded to arm, we selected viral load values closest to the scheduled data collection time points, within 30 days plus or minus scheduled time points at 3 months and 12 months after release. These values were used for 6 (2%) of the 315 3-month follow-ups and 23 (9%) of the 250 12-month follow-ups. The proportion of Casewatch values used did not differ significantly by arm.

Secondary outcome measures at each follow-up (collected using timeline follow-back)<sup>34</sup> included participant-

reported information on the following: linkage to HIV care after release (probability of HIV primary care visits); retention in HIV care (number of HIV primary care visits, given linkage); antiretroviral use and adherence; retention and adherence knowledge (10-item scale); physical and mental health as assessed by the 12-item short-form health survey (SF-12)<sup>35</sup>; and the numbers of specialty visits, mental health visits, case management visits, medication-assisted treatment visits, psychiatric hospital nights, emergency department visits, and days of substance use in the prior 30 days. We validated participant-reported visit data by electronic Casewatch visit records (eTable 2 in Supplement 2).

### Analysis

We examined the effect of the peer navigation intervention on viral suppression using intention-to-treat, generalized linear mixed models for longitudinally measured data. All models included random intercepts for participants and used a logistic link for viral suppression and all binary outcomes; linear link, normal models for continuous outcomes; and zero-inflated Poisson models for HIV primary care visits (retention) and all count data outcomes.<sup>36,37</sup> Adjusted probabilities of viral suppression were estimated at baseline, months 3 and 12 for the intervention and control arms, and differences in probabilities were estimated between arms, over time within arms, and difference-in-differences over 12 months (with 95% confidence intervals [CIs]). These models accommodate data missing at random; predictors include intervention arm, categorical time and intervention\*time interactions (see the statistical eAppendix in Supplement 2).<sup>35,36</sup> Finally, we modeled the effect of peer navigation on linkage to care as the binomial probability of at least 1 visit from baseline to 3, 6, and 12 months, by arm, and differences between arms (including 95% CIs).

To examine the heterogeneity of intervention effects, we explored potential effect modifiers of age, race/ethnicity, risk/gender group, education, income, insurance, substance use, SF-12 physical and mental health scores, and CD4 count, with all main effects, 2-way and 3-way interactions for intervention, time, and moderator predictors (including 95% CIs).

## Results

### Sample Characteristics

Among 465 screened inmates, 356 (78%) were eligible and randomized; 250 (70%) completed the 12-month interview (Figure). At baseline, the participants reported a mean (SD) age of 39.5 (10.4) years; 57% (n = 201) reported being men who have sex with men; 15% (n = 53), male to female transgender status; 42% (n = 150), an annual income of \$10 000 or less; 51% (n = 180), CD4 counts lower than 500 cells/mm<sup>3</sup>; and 56% (n = 199) no insurance (Table 1). Recent use of substances (opioids, stimulants, and binge alcohol) was prevalent (78%; n = 277), and mean SF-12 mental health was a standard deviation below the US national norm.<sup>35</sup> About half of the participants were virally suppressed (n = 184, 52%; 95% CI, 46%-57%).

Table 1. Baseline Characteristics of the Study Participants

Characteristics <sup>a</sup>	Study Participants, No. (%)			P Value <sup>b</sup>
	Intervention (n = 180)	Control (n = 176)	Total (n = 356)	
Age, y				.34
18-34	73 (41)	64 (36)	137 (39)	
35-49	78 (43)	73 (42)	151 (42)	
≥50	29 (16)	39 (22)	68 (19)	
Race/ethnicity				.58
White, non-Hispanic	47 (26)	48 (27)	95 (27)	
Black, non-Hispanic	81 (45)	70 (40)	151 (42)	
Hispanic	52 (29)	58 (33)	110 (31)	
HIV risk group/gender				.21
MSM contact	93 (52)	108 (61)	201 (57)	
Male heterosexual contact	36 (20)	23 (13)	59 (17)	
Male to female transgender	27 (15)	26 (15)	53 (15)	
Male IV drug use	24 (13)	19 (11)	43 (12)	
Educational attainment (n = 355)				.15
Less than high school	75 (42)	56 (32)	131 (37)	
High school or GED	47 (26)	49 (28)	96 (27)	
Some college or more	58 (32)	70 (40)	128 (36)	
Annual household income, \$ (n = 355)				.57
≤10 000	76 (42)	74 (42)	150 (42)	
10 001-20 000	45 (25)	51 (29)	96 (27)	
20 001-30 000	20 (11)	18 (10)	38 (11)	
30 001-50 000	10 (6)	13 (7)	23 (7)	
≥50 001	29 (16)	19 (11)	48 (14)	
Uninsured <sup>c</sup>	109 (61)	90 (51)	199 (56)	.07
Substance use				
Binge alcohol (n = 88) <sup>d</sup>	42 (23)	46 (26)	88 (25)	.54
Heroin (n = 24)	15 (8)	9 (5)	24 (7)	.23
Crack (n = 47)	18 (10)	29 (17)	47 (13)	.07
Cocaine (n = 23)	10 (6)	13 (7)	23 (7)	.48
Methamphetamine (n = 206)	104 (58)	102 (58)	206 (58)	.97
Oxycodone or other opiates (n = 15)	10 (6)	5 (3)	15 (4)	.20
Binge alcohol <sup>d</sup> and hard drug use <sup>e</sup>	135 (75)	142 (81)	277 (78)	.20
Other substances (n = 265) <sup>f</sup>	131 (73)	134 (76)	265 (74)	.47
Length of stay in jail, mean (SD), wk (n = 153)	33 (30)	32 (25)	33 (27)	.87
SF-12 mental health, mean (SD) <sup>g</sup>	39 (13)	38 (12)	38 (12)	.31
SF-12 physical health, mean (SD) <sup>g</sup>	51 (10)	51 (10)	51 (10)	.97
CD4 count, cells/mm <sup>3</sup> (n = 355)				.85
<200	21 (12)	17 (10)	38 (11)	
200-349	25 (14)	29 (17)	54 (15)	
350-499	44 (24)	44 (25)	88 (25)	
≥500	90 (50)	85 (49)	175 (49)	
Virally suppressed <sup>h</sup>	90 (50)	94 (53)	184 (52)	.60
Antiretroviral therapy				
Ever prescribed (n = 356)	159 (88)	159 (90)	318 (89)	.54
Currently using (n = 318)	147 (92)	149 (94)	296 (93)	.66
ART adherence (VAS), mean (SD) <sup>i</sup> (n = 269)	86 (24)	82 (26)	84 (25)	.36

(continued)

Table 1. Baseline Characteristics of the Study Participants (continued)

Characteristics <sup>a</sup>	Study Participants, No. (%)			P Value <sup>b</sup>
	Intervention (n = 180)	Control (n = 176)	Total (n = 356)	
Preincarceration utilization measures <sup>j</sup>				
HIV primary care visits (n = 350)	27 (15)	24 (14)	51 (15)	.75
Specialty care visits (n = 351)	22 (12)	26 (15)	48 (14)	.47
Mental health visits (n = 352)	58 (33)	54 (31)	112 (32)	.76
Case manager visits (n = 350)	71 (40)	63 (37)	134 (38)	.53
MAT visits (n = 352) <sup>k</sup>	44 (25)	46 (26)	90 (26)	.71
Psychiatric hospital nights (n = 351)	47 (26)	51 (29)	98 (28)	.52
ED visits (n = 351)	87 (49)	85 (49)	172 (49)	.96

Abbreviations: ART, antiretroviral therapy; ED, emergency department; GED, general equivalency diploma; HIV, human immunodeficiency virus; IV, intravenous; MAT, medication assisted treatment; MSM, men who have sex with men; SF-12, 12-item short-form health survey<sup>35</sup>; VAS, visual analogue scale.

<sup>a</sup> Data are reported as the total number of participants with nonmissing data on each item, generally n = 356; however, in categories where data were missing, the total number of participants for whom data were available is reported after each category name.

<sup>b</sup> Equality of the difference in proportions between study arms at baseline tested using the  $\chi^2$  test.

<sup>c</sup> Insured category (reference group) includes participants with private insurance (5%, n = 19), Medicaid/Medi-Cal (22%, n = 77), or other public insurance (17%, n = 61).

<sup>d</sup> Binge alcohol is defined as 5 or more alcoholic drinks at a time.

<sup>e</sup> Hard drugs include heroin, crack cocaine, powder cocaine,

methamphetamines, and/or oxycodone or other opiates.

<sup>f</sup> Other substances include marijuana, barbiturates, valium, or other sedative-hypnotics, ecstasy, LSD or other hallucinogens, and any alcohol.

<sup>g</sup> SF-12 Mental Component and Physical Component Scores (T-scores, normed to US general population: mean (SD) score, 50 (10)).<sup>35</sup>

<sup>h</sup> Defined as undetectable viral load, based on the laboratory limit of detection  $\leq 75$  copies/mL.

<sup>i</sup> ART adherence is defined as the mean percentage of ART doses taken, among those prescribed and using ART, measured using a VAS.

<sup>j</sup> Included are participants who reported at least 1 visit of the specified type in the 12 months prior to incarceration, measured by timeline follow-back.

<sup>k</sup> MAT visits include those for prescription medications such as methadone or buprenorphine to treat addiction to drugs or alcohol.

Table 2. Effect of the LINK LA Intervention on Viral Suppression<sup>a</sup> After Jail Release

Measurement Time	No./No. (Probability <sup>b</sup> )		Probability Difference (95% CI) <sup>c</sup>	P Value <sup>d</sup>
	Intervention	Control		
Baseline (n = 356)	88/180 (0.49)	91/176 (0.52)	-0.04 (-0.18 to 0.10)	.60
3 Months (n = 315)	82/157 (0.53)	63/158 (0.37)	0.16 (0.01 to 0.31)	.03
Change at 3 months (95% CI) <sup>c,e</sup>	0.04 (-0.08 to 0.17)	-0.16 (-0.28 to -0.03) <sup>f</sup>	0.20 (0.02 to 0.38)	.02
12 Months (n = 250)	62/125 (0.49)	45/125 (0.30)	0.18 (0.02 to 0.40)	.03
Change at 12 months (95% CI) <sup>c,e</sup>	0.003 (-0.130 to 0.140)	-0.22 (-0.35 to -0.09) <sup>g</sup>	0.22 (0.03 to 0.41)	.02

Abbreviations: GLMM, generalized linear mixed model; LINK LA, Linking Inmates to Care in Los Angeles.

<sup>a</sup> Viral suppression is measured as the probability of having an undetectable viral load (<75 copies/mL) at each follow-up session by study arm using a repeated measures, random-intercept, logistic model (a GLMM) with predictors of study arm, categorical time, and intervention  $\times$  time interaction. The model accommodates data missing at random, and loss to follow-up was not different between study arms.

<sup>b</sup> Probability is not necessarily equal to the numerator divided by the denominator because the probabilities are estimated from the

random-intercept, logistic GLMMs.

<sup>c</sup> Intervention arm value minus control arm value; probability differences are not always precise totals owing to rounding.

<sup>d</sup> P value for test between intervention and control arm values at each follow-up period and difference-in-difference tested for change from baseline by study arm, based on the single random-intercept, logistic GLMM.

<sup>e</sup> Follow-up interview value minus baseline value.

<sup>f</sup> P < .05 for change from baseline.

<sup>g</sup> P < .01 for change from baseline.

### Effects of Peer Navigation on Viral Suppression

At 12 months, 62 (49.6%) of 125 participants had achieved viral suppression in the peer navigation arm compared with 45 (36.0%) of 125 in the transitional case management arm, for an unadjusted treatment difference of 13.6% (95% CI, 1.3%-25.9%; P = .03). In the repeated measures analysis, the peer navigation arm's adjusted probabilities of viral suppression did not change from 49% at baseline to 49% at month 12, while it declined from 52% at baseline to 30% at 12 months in the transitional case management arm (Table 2). Thus, the difference-

in-difference of viral suppression probability over 12 months was 22% (95% CI, 3%-41%; P = .02).

### Secondary Outcomes

There was no significant difference between arms in the probability of having at least 1 postrelease HIV primary care visit (linkage) at 12 months, but the probability of linkage was greater in the peer navigation arm at 6 months (difference, 12%; 95% CI, 4%-22%; P = .01; Table 3). Among those with at least 1 visit, there was a greater increase from base-

Table 3. Effect of the LINK LA Intervention on Linkage to and Retention in HIV Primary Care After Jail Release<sup>a</sup>

Measurement Time	Intervention (95% CI) (n = 180)	Control (95% CI) (n = 176)	Difference (95% CI) <sup>b,c</sup>	P Value <sup>d</sup>
<b>Linkage to HIV Care<sup>e</sup></b>				
0-3 Months (n = 312)	0.64 (0.57 to 0.72)	0.63 (0.56 to 0.71)	0.01 (-0.09 to 0.12)	.81
0-6 Months (n = 260)	0.89 (0.84 to 0.95)	0.77 (0.69 to 0.84)	0.12 (0.04 to 0.22)	.01
0-12 Months (n = 220)	0.92 (0.87 to 0.97)	0.88 (0.82 to 0.94)	0.04 (-0.04 to 0.12)	.32
<b>Retention in HIV Care<sup>f</sup></b>				
Baseline (n = 350)	1.64 (1.29 to 2.00)	2.26 (1.74 to 2.77)	-0.61 (-1.24 to 0.01) <sup>g</sup>	.054
3 Months (n = 312)	3.08 (2.56 to 3.61)	3.04 (2.52 to 3.55)	0.04 (-0.69 to 0.77)	.90
Change at 3 months (n = 307) <sup>a,c</sup>	1.44 (0.89 to 1.98) <sup>h</sup>	0.78 (0.18 to 1.38) <sup>g</sup>	0.66 (-0.15 to 1.47)	.11
6 Months (n = 261)	2.15 (1.79 to 2.50)	2.15 (1.75 to 2.55)	-0.001 (-0.54 to 0.53)	>.99
Change at 6 months (n = 256) <sup>a,c</sup>	0.50 (0.10 to 0.90) <sup>g</sup>	-0.11 (-0.66 to 0.44)	0.61 (-0.07 to 1.30)	.08
12 Months (n = 235)	2.25 (1.87 to 2.64)	2.16 (1.79 to 2.53)	0.09 (-0.44 to 0.62)	.73
Change at 12 months (n = 232) <sup>a,c</sup>	0.61 (0.17 to 1.06) <sup>g</sup>	-0.10 (-0.63 to 0.44)	0.71 (0.01 to 1.40) <sup>g</sup>	.047

Abbreviations: GLMM, generalized linear mixed model; HIV, human immunodeficiency virus; LINK LA, Linking Inmates to Care in Los Angeles; ZIP, zero-inflated Poisson.

<sup>a</sup> Follow-up interview value minus baseline value.

<sup>b</sup> Intervention arm estimate minus control arm estimate.

<sup>c</sup> Difference and change values are not always precise totals owing to rounding.

<sup>d</sup> P value for test between intervention and control arm values at each measurement time and difference-in-difference tested for change from baseline by study arm, based on a single regression model.

<sup>e</sup> Probability of having HIV primary care visits from baseline (0 months) to each measurement time at 3, 6, and 12 months after release from incarceration by arm, and difference (with 95% CIs) estimated using unadjusted binomial model.

<sup>f</sup> Estimated number of HIV primary care visits over the preceding 3 months, given linkage to care (at least 1 visit), using a repeated measures, random-intercept, ZIP model (a GLMM) with predictors of intervention arm, categorical time, and intervention × time interaction. The model accommodates data missing at random, and loss to follow-up was not different between study arms. ZIP models had 2 uncorrelated random effects, one for the zero-inflation component and the other for the Poisson component. All values are estimated per-12-month rate, given at least 1 visit (or hospital night) in the previous 12 months.

<sup>g</sup> P < .05 for change from baseline.

<sup>h</sup> P < .001 for change from baseline

line in the number of visits per year (retention) since release in the peer navigation arm than in the control arm over 12 months (difference, 0.71; 95% CI, 0.01-1.40;  $P = .047$ ) (Table 3). While the intervention improved retention and adherence knowledge at 12 months, more than 90% of participants (n = 296 of 321) reported currently using antiretroviral therapy in both arms and all follow-up periods (Table 4). Similarly, mean self-reported adherence exceeded 80% in both arms and all follow-up periods. Peer navigation arm participants reported a greater increase in number per year of mental health visits at 3 months (21.6; 95% CI, 12.2-31.0;  $P < .001$ ) and 6 months (13.6; 95% CI, 7.0-20.2;  $P < .001$ ), case management visits at 3 months (10.0; 95% CI, 4.3-15.8;  $P < .001$ ) and 6 months (14.3; 95% CI, 9.9-18.7;  $P < .001$ ), medication-assisted treatment visits at 6 months (2.4; 95% CI, 0.02-4.8;  $P = .048$ ), psychiatric hospital nights at 3 months (125.3; 95% CI, 36.4-214.2;  $P = .01$ ); and they had fewer emergency department visits at 3 months (-1.2; 95% CI, -2.0 to -0.3;  $P = .01$ ) and 6 months (-0.5; 95% CI, -0.9 to -0.1;  $P = .005$ ). Control arm participants had a greater increase in the number of specialty visits at 3 months and medication-assisted treatment visits at 12 months. There was no effect on reported substance use, although use declined substantially in both arms, particularly at 3 months, and remained lower than baseline at 12 months (eTable 3 in Supplement 2).

### Substance Use and Other Potential Moderators

We hypothesized that the intervention effect would be greater among non-substance users than among substance users, but

the evidence did not support this. However, the intervention was most effective at 12 months among the homeless ( $P = .004$  for the interaction) and those who were virally suppressed at baseline ( $P < .001$  for the interaction). See eTable 4 in Supplement 2 for supporting data.

## Discussion

In this study of people living with HIV released from a large metropolitan jail, the LINK LA peer navigation intervention better maintained viral suppression over 12 months than transitional case management, for a 22% adjusted difference-in-difference. No prior interventions to our knowledge have shown a sustained level of viral suppression after jail release among people living with HIV reentering the community. A randomized clinical trial<sup>14</sup> comparing a motivational interviewing/care-coordination intervention with standard care found about 60% viral suppression in both arms at 6 months after release from 2 southern US prisons and temporal declines in both arms from over 85% before release. Two recently published trials of somewhat similar interventions (patient navigation,<sup>18</sup> peer mentors<sup>38</sup>) among people living with HIV after hospitalization did not find that viral suppression was significantly better in the intervention groups than among controls at 12 months. However, attending more patient navigation sessions was associated with improved viral suppression at 6 months in the trial of patient navigation plus financial incentives.<sup>18,39</sup> Although the level of viral suppression did not increase from baseline in LINK LA, the peer navigation



Table 4. Effect of the LINK LA Intervention on Secondary Outcomes After Jail Release<sup>a</sup>

Measurement Time	No./Total No.; Probability (95% CI)		Difference (95% CI) <sup>b</sup>	P Value <sup>c</sup>
	Intervention	Control		
<b>Current ART Use<sup>d</sup></b>				
Baseline (n = 321)	147/161; 0.98 (0.96 to 1.00)	149/160; 0.99 (0.97 to 1.00)	-0.01 (-0.03 to 0.01)	.49
3 Months (n = 315)	128/157; 0.94 (0.90 to 0.99)	130/158; 0.95 (0.92 to 0.99)	-0.01 (-0.06 to 0.04)	.69
Change at 3 months <sup>b,e</sup>	-0.040 (-0.070 to 0.001)	-0.0300 (-0.0700 to -0.0002) <sup>f</sup>	-0.003 (-0.050 to 0.050)	.90
6 Months (n = 285)	116/143; 0.94 (0.89 to 0.98)	111/142; 0.92 (0.86 to 0.98)	0.02 (-0.05 to 0.08)	.65
Change at 6 months <sup>b,e</sup>	-0.0400 (-0.0800 to 0.0001) <sup>f</sup>	-0.07 (-0.12 to -0.01)	0.02 (-0.04 to 0.09)	.49
12 Months (n = 250)	104/125; 0.95 (0.91 to 0.99)	107/125; 0.96 (0.93 to 0.996)	-0.01 (-0.06 to 0.03)	.60
Change at 12 months <sup>b,e</sup>	-0.03 (-0.07 to 0.01)	-0.02 (-0.05 to 0.01)	-0.01 (-0.05 to 0.04)	.82
<b>Adherence to ART<sup>g,h</sup></b>				
Baseline (n = 354)	(98) 85.7 (80.8 to 90.7)	(109) 81.6 (76.9 to 86.3)	4.1 (-2.7 to 10.9)	.54
3 Months (n = 315)	(116) 85.1 (80.7 to 89.5)	(121) 82.6 (78.3 to 86.9)	2.5 (-3.6 to 8.7)	.40
Change at 3 months <sup>b,e</sup>	-0.6 (-7.3 to 6.0)	0.95 (-5.5 to 7.4)	-1.6 (-10.8 to 7.7)	.38
6 Months (n = 285)	(110) 88.4 (84.5 to 92.3)	(101) 86.1 (82.0 to 90.1)	2.4 (-3.3 to 8.0)	.20
Change at 6 months <sup>b,e</sup>	2.7 (-3.4 to 8.8)	4.5 (-1.5 to 1.4)	-1.8 (-10.3 to 6.7)	.14
12 Months (n = 250)	(96) 86.7 (82.4 to 91.1)	(101) 85.4 (81.2 to 89.7)	1.3 (-4.8 to 7.4)	.50
Change at 12 months <sup>b,e</sup>	1.0 (-5.4 to 7.4)	3.8 (-2.3 to 9.9)	-2.8 (-11.6 to 6.1)	.20
<b>Retention and Adherence Knowledge<sup>h,i</sup></b>				
Baseline (n = 354)	(176) 8.9 (8.7 to 9.0)	(176) 9.0 (8.8 to 9.1)	-0.1 (-0.3 to 0.1)	.35
3 Months (n = 315)	(158) 8.9 (8.8 to 9.1)	(158) 9.0 (8.9 to 9.2)	-0.1 (-0.3 to 0.1)	.42
Change at 3 months <sup>b,e</sup>	0.06 (-0.10 to 0.30)	0.05 (-0.10 to 0.30)	0.01 (-0.30 to 0.30)	.95
6 Months (n = 285)	(142) 9.0 (8.8 to 9.1)	(142) 9.05 (8.90 to 9.20)	-0.1 (-0.3 to 0.1)	.40
Change at 6 months <sup>b,e</sup>	0.08 (-0.1 to 0.3)	0.07 (-0.10 to 0.30)	0.01 (-0.30 to 0.30)	.95
12 Months (n = 250)	(125) 9.2 (9.0 to 9.3)	(125) 9.0 (8.8 to 9.1)	0.20 (-0.06 to 0.40)	.14
Change at 12 months <sup>b,e</sup>	0.30 (0.08 to 0.5) <sup>j</sup>	-0.002 (-0.200 to 0.200)	0.30 (0.01 to 0.60) <sup>f</sup>	.04
<b>SF-12 Physical Health<sup>h,k</sup></b>				
Baseline (n = 352)	(180) 51.4 (49.9 to 53.0)	(172) 51.4 (49.9 to 53.0)	0.02 (-2.1 to 2.2)	.99
3 Months (n = 309)	(154) 48.5 (46.8 to 50.2)	(155) 47.9 (46.2 to 49.6)	0.5 (-1.9 to 2.9)	.67
Change at 3 months <sup>b,e</sup>	-3.0 (-4.6 to -1.4) <sup>l</sup>	-3.5 (-5.1 to -1.9) <sup>l</sup>	0.5 (-1.8 to 2.8)	.66
6 Months (n = 274)	(138) 48.5 (46.7 to 50.3)	(136) 48.2 (46.4 to 49.9)	0.4 (-2.2 to 2.9)	.77
Change at 6 months <sup>b,e</sup>	-2.9 (-4.8 to -1.0) <sup>j</sup>	-3.3 (-5.2 to -1.4) <sup>l</sup>	0.4 (-2.3 to 3.0)	.80
12 Months (n = 248)	(124) 48.6 (46.8 to 50.5)	(124) 46.5 (44.7 to 48.3)	2.1 (-0.5 to 4.7)	.11
Change at 12 months <sup>b,e</sup>	-2.8 (-4.7 to -0.9) <sup>j</sup>	-4.9 (-6.9 to -3.0) <sup>l</sup>	2.1 (-0.6 to 4.8)	.13
<b>SF-12 Mental Health<sup>h,k</sup></b>				
Baseline (n = 352)	(180) 38.9 (37.1 to 40.7)	(172) 37.6 (35.7 to 39.4)	1.3 (-1.3 to 3.9)	.32
3 Months (n = 309)	(154) 41.0 (39.1 to 42.9)	(155) 39.9 (38.0 to 41.8)	1.1 (-1.6 to 3.8)	.42
Change at 3 months <sup>b,e</sup>	2.10 (0.08 to 4.20) <sup>f</sup>	2.3 (0.3 to 4.4) <sup>f</sup>	-0.2 (-3.1 to 2.7)	.88
6 Months (n = 274)	(138) 40.4 (38.4 to 42.4)	(136) 40.7 (38.7 to 42.7)	-0.3 (-3.1 to 2.5)	.84
Change at 6 months <sup>b,e</sup>	1.5 (-0.5 to 3.5)	3.1 (1.1 to 5.1) <sup>j</sup>	-1.6 (-4.4 to 1.2)	.27
12 Months (n = 248)	(124) 40.1 (38.0 to 42.2)	(120) 41.3 (39.2 to 43.4)	-1.2 (-4.1 to 1.8)	.44
Change at 12 months <sup>b,e</sup>	1.3 (-0.9 to 3.4)	3.7 (1.6 to 5.9) <sup>l</sup>	-2.5 (-5.5 to 0.6)	.11
<b>Specialty Care Visits<sup>m</sup></b>				
Baseline (n = 351)	22/178; 3.8 (2.8 to 4.9)	26/173; 5.3 (3.3 to 7.2)	-1.4 (-3.6 to 0.7)	.19
3 Months (n = 311)	34/156; 3.6 (2.5 to 4.7)	31/155; 6.5 (4.0 to 8.9)	-2.8 (-5.5 to -0.2)	.04
Change at 3 months <sup>b</sup>	-0.2 (-1.3 to 0.9)	1.2 (-1.2 to 3.6)	-1.4 (-4.0 to 1.2)	.30
6 Months (n = 262)	39/133; 3.6 (2.6 to 4.5)	36/129; 4.4 (3.1 to 5.7)	-0.8 (-2.4 to 0.7)	.30
Change at 6 months <sup>b</sup>	-0.3 (-1.1 to 0.6)	-0.9 (-2.7 to 1.0)	0.6 (-1.4 to 2.6)	.55
12 Months (n = 235)	38/117; 6.9 (4.6 to 9.2)	35/118; 7.0 (4.5 to 9.5)	-0.1 (-3.4 to 3.3)	.97
Change at 12 months <sup>b</sup>	3.1 (1.3 to 5.0) <sup>l</sup>	1.7 (-0.7 to 4.2)	1.4 (-1.7 to 4.5)	.38
<b>Mental Health Visits<sup>n</sup></b>				
Baseline (n = 352)	58/178; 10.1 (6.5 to 13.6)	54/174; 10.2 (6.4 to 14.1)	-0.1 (-4.8 to 4.5)	.95
3 Months (n = 310)	48/156; 31.9 (19.6 to 44.2)	43/154; 10.4 (6.1 to 14.7)	21.5 (9.2 to 33.8)	<.001
Change at 3 months <sup>b</sup>	21.8 (12.7 to 30.9) <sup>l</sup>	0.2 (-2.3 to 2.7)	21.6 (12.2 to 31.0) <sup>l</sup>	<.001
6 Months (n = 261)	53/133; 24.6 (15.2 to 34.0)	44/128; 11.1 (6.6 to 15.6)	13.5 (3.8 to 23.1)	.01
Change at 6 months <sup>b</sup>	14.5 (8.3 to 20.8) <sup>l</sup>	0.9 (-1.4 to 3.2)	13.6 (7.0 to 20.2) <sup>l</sup>	<.001
12 Months (n = 235)	40/117; 14.7 (9.0 to 20.4)	40/118; 20.2 (11.8 to 28.7)	-5.5 (-14.9 to 3.8)	.25
Change at 12 months <sup>b</sup>	4.6 (1.6 to 7.6) <sup>j</sup>	10.0 (4.7 to 15.3) <sup>l</sup>	-5.4 (-11.4 to 0.6)	.08

(continued)

Table 4. Effect of the LINK LA Intervention on Secondary Outcomes After Jail Release<sup>a</sup> (continued)

Measurement Time	No./Total No.; Probability (95% CI)		Difference (95% CI) <sup>b</sup>	P Value <sup>c</sup>
	Intervention	Control		
<b>Case Manager Visits<sup>d</sup></b>				
Baseline (n = 351)	71/178; 9.6 (6.8 to 12.4)	63/172; 10.9 (7.9 to 14.0)	-1.3 (-5.0 to 2.3)	.47
3 Months (n = 311)	100/156; 25.5 (17.7 to 33.3)	78/155; 16.9 (12.1 to 21.6)	8.7 (0.4 to 17.0)	.04
Change at 3 months <sup>b</sup>	16.0 (10.6 to 21.3) <sup>i</sup>	5.9 (3.3 to 8.6) <sup>i</sup>	10.0 (4.3 to 15.8)	<.001
6 Months (n = 262)	66/133; 19.7 (13.6 to 25.8)	53/128; 6.7 (4.9 to 8.5)	13.0 (6.9 to 19.0)	<.001
Change at 6 months <sup>b</sup>	10.1 (6.3 to 14.0) <sup>i</sup>	-4.2 (-6.1 to -2.3) <sup>i</sup>	14.3 (9.9 to 18.7)	<.001
12 Months (n = 235)	54/117; 11.3 (7.8 to 14.7)	57/118; 10.7 (7.6 to 13.9)	0.5 (-3.7 to 4.7)	.81
Change at 12 months <sup>b</sup>	1.7 (-0.1 to 3.5)	-0.2 (-2.1 to 1.7)	1.9 (-0.8 to 4.5)	.17
<b>Medication Assisted Treatment Visits<sup>d</sup></b>				
Baseline (n = 351)	4/178; 6.9 (4.8 to 9.0)	5/173; 4.5 (3.3 to 5.8)	2.3 (-0.1 to 4.7)	.06
3 Months (n = 311)	10/156; 7.5 (4.7 to 10.2)	3/155; 4.7 (3.1 to 6.4)	2.7 (-0.5 to 5.9)	.09
Change at 3 months <sup>b</sup>	0.6 (-1.5 to 2.7)	0.2 (-1.2 to 1.6)	0.4 (-2.1 to 2.9)	.76
6 Months (n = 262)	11/133; 8.8 (5.4 to 13.1)	4/129; 4.0 (2.8 to 5.2)	4.7 (1.6 to 7.9)	.003
Change at 6 months <sup>b</sup>	1.6 (-0.1 to 3.3)	-0.6 (-1.6 to 0.5)	2.40 (0.02 to 4.80) <sup>f</sup>	.05
12 Months (n = 235)	3/117; 5.5 (3.5 to 7.5)	9/118; 7.3 (4.7 to 9.9)	-1.8 (-5.1 to 1.5)	.28
Change at 12 months <sup>b</sup>	-1.4 (-3.2 to 0.4)	2.8 (0.8 to 4.7) <sup>j</sup>	-4.1 (-6.8 to -1.5) <sup>i</sup>	.002
<b>Nights Spent in Psychiatric Hospitals</b>				
Baseline (n = 351)	47/178; 118.6 (70.7 to 166.6)	51/173; 95.7 (57.0 to 134.5)	22.9 (-28.8 to 74.6)	.38
3 Months (n = 311)	56/156; 342.2 (204.2 to 480.1)	34/155; 194.0 (115.0 to 273.0)	148.2 (11.5 to 284.4)	.03
Change at 3 months <sup>b</sup>	223.5 (132.4 to 314.7) <sup>i</sup>	98.3 (56.2 to 140.3) <sup>i</sup>	125.3 (36.4 to 214.2) <sup>j</sup>	.01
6 Months (n = 262)	34/133; 254.8 (151.8 to 357.8)	25/129; 318.9 (188.7 to 449.0)	-64.1 (-203.5 to 75.3)	.37
Change at 6 months <sup>b</sup>	136.1 (79.5 to 192.8) <sup>i</sup>	223.1 (13.4 to 315.9) <sup>i</sup>	-87.0 (-180.7 to -6.7)	.07
12 Months (n = 235)	27/117; 265.9 (157.9 to 373.8)	25/118; 287.8 (169.9 to 405.7)	-21.9 (-155.6 to 111.7)	.08
Change at 12 months <sup>b</sup>	147.3 (85.3 to 209.2) <sup>i</sup>	192.1 (111.3 to 272.9) <sup>i</sup>	-44.8 (-131.5 to 41.9)	.31
<b>Emergency Department Visits<sup>d</sup></b>				
Baseline (n = 351)	87/178; 4.1 (3.3 to 5.0)	85/173; 2.9 (2.4 to 3.4)	1.2 (0.4 to 2.1)	.01
3 Months (n = 311)	47/156; 3.3 (2.6 to 4.0)	37/155; 3.2 (2.5 to 4.0)	-0.06 (-0.8 to 0.9)	.89
Change at 3 months <sup>b</sup>	-0.8 (-1.5 to -0.2) <sup>f</sup>	0.30 (-0.20 to 0.90)	-1.2 (-2.0 to -0.3) <sup>j</sup>	.01
6 Months (n = 262)	42/133; 3.8 (2.9 to 4.6)	38/128; 4.4 (3.2 to 5.6)	-0.6 (-2.0 to 0.8)	.38
Change at 6 months <sup>b</sup>	-0.3 (-1.0 to 0.3)	1.5 (0.5 to 2.5) <sup>j</sup>	-1.8 (-3.1 to -0.6) <sup>j</sup>	.004
12 Months (n = 235)	37/117; 5.0 (3.6 to 6.4)	43/118; 3.6 (2.7 to 4.5)	1.4 (-0.1 to 3.0)	.07
Change at 12 months <sup>b</sup>	0.9 (-0.1 to 1.9)	0.70 (-0.02 to 1.40)	0.2 (-1.0 to 1.5)	.74

Abbreviations: ART, antiretroviral therapy; GLMM, generalized linear mixed model; LINK LA, Linking Inmates to Care in Los Angeles; SF-12, 12-item short-form health survey<sup>35</sup>; ZIP, zero-inflated Poisson.

<sup>a</sup> Estimated values of each secondary outcome variable using repeated measures, random-intercept, ZIP models (for count data variables, ie, the health care services utilization variables), logistic link models (for binary, 0/1 variables), and linear link, normal GLMMs (for continuous variables) with predictors of intervention arm, categorical time, and intervention × time interaction term. The model accommodates data missing at random, and we conducted analysis to determine that loss to follow-up was not different between study arms. The ZIP models had 2 uncorrelated random effects, one for the zero-inflation component and the other for the Poisson component. All values are estimated at a per 12-month-rate, given at least 1 visit (or hospital night) in the previous 12 months.

<sup>b</sup> Difference and change values are not always precise totals owing to rounding.

<sup>c</sup> P value for test between intervention and control arm values at each follow-up time, and difference-in-difference tested for change from baseline by study arm, based on a single regression model.

<sup>d</sup> Probability of reporting currently using (yes/no) at least 1 of a list of all available ART medications (list available at <https://aidsinfo.nih.gov/drugs>).

<sup>e</sup> Follow-up interview value minus baseline value.

<sup>f</sup> P < .05 for change from baseline.

<sup>g</sup> Adherence was measured using a visual analogue scale, mean percentage from 0 to 100, where 100 indicates perfect adherence.

<sup>h</sup> The first parenthetical number in this category reports the number of nonmissing observations from participants who responded.

<sup>i</sup> Mean number of knowledge items (yes/no) answered correctly on a 10-item measure.

<sup>j</sup> P < .01 for change from baseline.

<sup>k</sup> SF-12 values are T-scores, normed relative to a US mean (SD) of 50 (10).<sup>35</sup>

<sup>l</sup> P < .001 for change from baseline.

<sup>m</sup> Reported as mean number of office visits with physicians for specialty care, such as ophthalmologist for an eye problem.

<sup>n</sup> Reported as mean number of visits to get counseling for psychological or emotional problems.

<sup>o</sup> Reported as mean number of visits to case managers.

<sup>p</sup> Reported as mean number of visits to a physician to get prescription medications to treat drug or alcohol problem.

<sup>q</sup> Reported as mean number of visits to the emergency department.

intervention was successful at preventing the declines in viral suppression usually observed after release from incarceration.<sup>9,12,13,40,41</sup>

The baseline probability of 49% viral suppression sustained by LINK LA participants in the intervention arm is com-

parable to that observed in other studies of incarcerated people living with HIV,<sup>39,42</sup> while suppression among controls declined to 30% at 12 months. Achievement of viral suppression is important because it promotes immune reconstitution and virtually eliminates HIV transmission.<sup>43</sup> Also, the 49%

12-month viral suppression probability found in LINK LA is substantially greater than the 24% to 39% levels estimated nationally and the 30% seen among our controls.<sup>41,44</sup> In addition, the decline in viral suppression among controls is consistent with the decline over time in adherence verified by medication event monitoring systems observed across 14 US adherence studies.<sup>40</sup> The control condition also represents a fairly robust test of the LINK LA peer navigation intervention because transitional case management has been effective at improving linkage to medical and supportive services after incarceration in some studies.<sup>45,46</sup>

The LINK LA peer navigation intervention is distinct from previously published HIV navigation interventions tested in randomized trials. First, the peers were not “matched” to participants based on demographic characteristics as in some patient navigation interventions, but rather were selected for experience relevant to postincarcerated persons. Second, LINK LA was designed more as a behavior change intervention rather than as another “wraparound” service (eg, case management), as patient navigation has been described in some literature.<sup>18</sup> Third, we conducted key curriculum sessions during 2 accompaniments to HIV care, conveying important concepts in context and modeling patient behavior. One review of interventions to enhance retention in HIV care defined accompaniment as a separate kind of intervention from patient navigation.<sup>16</sup> Some navigation interventions consisted of accompaniment to 1 HIV care visit.<sup>19,47-50</sup> Fourth, LINK LA facilitated communication with clinicians during visits and follow through on their recommendations afterwards. Few other navigation interventions have included this component,<sup>51</sup> but some work points to the critical role of the patient-clinician relationship in HIV care retention among postincarcerated persons and other persons living with HIV.<sup>51,52</sup> Finally, previous peer mentor and peer support interventions used non-full-time staff,<sup>38</sup> whereas our peer navigators were staff members paid full-time salaries with benefits, resulting in little turnover. Perhaps these differences help to explain why the LINK LA peer navigation intervention was successful, in contrast to those using other navigation models.

LINK LA peer navigation also improved self-reported retention in HIV primary care, as well as retention and adherence knowledge at 12 months, supporting the viral suppression outcome finding and suggesting a possible mechanism consistent with the conceptual model. Moreover, LINK LA improved the use of mental health care and case management<sup>53</sup> in the community, while it reduced emergency department visits,<sup>54</sup> further supporting the main outcome findings. LINK LA was also particularly effective for those who were homeless before incarceration. However, it did not signifi-

cantly improve self-reported antiretroviral use or adherence. More than 90% of participants reported antiretroviral use, and adherence exceeded 80% at all follow-up times and both arms, suggesting possible overreporting.<sup>55</sup> A somewhat similar randomized clinical trial of the effect of patient navigation and financial incentives on viral suppression among people living with HIV discharged from hospitals demonstrated a similar gap (30%-40% difference) between self-reported adherence and viral suppression proportions.<sup>18</sup>

### Limitations

There were several limitations to this study. Although viral load tests were conducted by laboratory assay, baseline measures were collected by jail staff rather than research staff, so we lacked control over the test conditions, and results were often reported only as detectable or undetectable, rather than number of copies per milliliter. Thus, our outcome evaluation was limited to assessing only binary viral suppression outcomes rather than change in viral load level. Since this limitation was not differential by intervention arm, it should not have biased our key findings, but it reduced our power to detect smaller changes. Approximately half of the sample had viral suppression at baseline, limiting our detection of improvement over time. Attrition also limited power to detect effects, but fortunately, study retention was 70% at 12 months; attrition was not differential by arm; and we replaced a small amount of missing data on the outcome using public health data. Finally, covariates and secondary outcomes were self-reported by the participants. Although the measure we used was previously validated,<sup>56</sup> self-reported antiretroviral medication adherence is often an overestimate.<sup>57</sup> In fact, more than 26% of those with detectable viral load reported 100% adherence, a level reported by 42% of the overall sample.<sup>58-60</sup> Therefore, it might be expected that we found significant effects on viral suppression but did not find these effects for self-reported antiretroviral therapy adherence.

### Conclusions

Despite these limitations, this study provides evidence of an effect of the LINK LA peer navigation intervention sustaining the level of viral suppression over 12 months, curtailing the typical decline in viral suppression observed among postincarcerated people living with HIV. While our data may generalize to other large municipal jails, future research should examine ways to further improve viral suppression among people living with HIV after release from incarceration.

#### ARTICLE INFORMATION

**Accepted for Publication:** January 5, 2018.

**Published Online:** March 12, 2018.  
doi:10.1001/jamainternmed.2018.0150

**Author Affiliations:** Department of Medicine, Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles (Cunningham,

Nakazono, Ettner, Harawa); Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles (Cunningham, Ettner); Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles (Weiss); Los Angeles County Sheriff's, Los Angeles, California (Malek); Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles

(Malek, Harawa); Department of Family Medicine, Geffen School of Medicine, University of California, Los Angeles (Shoptaw); Charles R. Drew University College of Medicine, Los Angeles, California (Harawa).

**Author Contributions:** Dr Cunningham had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Cunningham, Weiss, Malek, Shoptaw, Ettner, Harawa.

**Acquisition, analysis, or interpretation of data:** All authors.

**Drafting of the manuscript:** Cunningham, Weiss, Nakazono, Malek, Shoptaw, Harawa.

**Critical revision of the manuscript for important intellectual content:** Cunningham, Weiss, Malek, Shoptaw, Ettner, Harawa.

**Statistical analysis:** Cunningham, Weiss, Nakazono, Malek, Ettner.

**Obtained funding:** Cunningham, Malek.

**Administrative, technical, or material support:** Cunningham, Malek, Harawa.

**Study supervision:** Cunningham, Weiss, Malek.

**Conflict of Interest Disclosures:** Dr Shoptaw has received clinical supplies from MediciNova Inc for a different clinical trial. No other disclosures are reported.

**Funding/Support:** Primary support for this research was provided by a grant from NIH/NIDA, R01 DA030781 (PI, WE Cunningham). Additional support for time on this analysis (Weiss, Shoptaw, Harawa, Cunningham) was provided by the Center for HIV Identification, Prevention, and Treatment (CHIPTS) NIMH grant P30-MH58107.

Dr Cunningham's time was also supported in part by NIDA R01-DA039934 (MPls, Schneider, Harawa, Kayo); NIMH R01-MH103076 (PI, Cunningham); NIA P30-AG021684 (RCMAR/CHIME; PI Mangione); NIMHD R01-MD011773 (PI, Cunningham); NINR Grants: R01-NR017334 (PI, Bogart), and R01-NR4014789 (PI, Ford); and the UCLA Clinical and Translational Science Institute (CTSI) NIH/NCATS grants ULI-TRO01881 (PI, Dubinett) and TL1-TRO01883 (PI, Ettner).

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Disclaimer:** The content is solely the responsibility of the authors and does not necessarily represent the views of the NIH.

**Additional Contributions.** We thank the following individuals for their contributions to the study: Jimmy Ngo, BA; Danielle Seiden, MPP; Jenna Arzinger, MPH; Darlene Hernandez; Garret Cox, MPH; Martha Tadesse, RN; Diana Perez, RN; Joanne Oliver; Maria Meligitone; Al Brown; Richard Hamilton; the many leaders and staff of the Division of HIV and STD Programs, LA County Department of Public Health, the LA County Sheriff's Department, and the study participants living with HIV. They received no compensation for their contributions beyond that received in the normal course of their employment or that reported in this article.

## REFERENCES

- Giordano TP, Suarez-Almazor ME, Grimes RM. The population effectiveness of highly active antiretroviral therapy: are good drugs good enough? *Curr HIV/AIDS Rep*. 2005;2(4):177-183.
- Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. *Clin Infect Dis*. 2011;52(6):793-800.

- Tobias C, Cunningham WE, Cunningham CO, Pounds MB. Making the connection: the importance of engagement and retention in HIV medical care. *AIDS Patient Care STDS*. 2007;21(suppl 1):S3-S8.
- Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. *PLoS One*. 2009;4(11):e7558.
- Sabin KM, Frey RL Jr, Horsley R, Greby SM. Characteristics and trends of newly identified HIV infections among incarcerated populations: CDC HIV voluntary counseling, testing, and referral system, 1992-1998. *J Urban Health*. 2001;78(2):241-255.
- Maruschak LM. U.S. Department of Justice, Office of Justice Programs; Bureau of Justice Statistics. HIV in Prisons, 2006. April 22, 2008. <https://www.bjs.gov/content/pub/pdf/hivp06.pdf>. Accessed January 16, 2018.
- Harawa NT, Amani B, Bowers JR, Sayles JN, Cunningham WE. Understanding interactions of formerly incarcerated HIV-positive men and transgender women with substance use treatment, medical, and criminal justice systems. *Int J Drug Policy*. 2017;Oct(48):63-71.
- Draine J, Ahuja D, Altice FL, et al. Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. *AIDS Care*. 2011;23(3):366-377.
- Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. *Clin Infect Dis*. 2004;38(12):1754-1760.
- Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. *JAMA Intern Med*. 2014;174(5):721-729.
- Rapp RC, Ciomcia R, Zaller N, Draine J, Ferguson A, Cagey R. The role of jails in engaging PLWHA in care: from jail to community. *AIDS Behav*. 2013;17(suppl 2):S89-S99.
- Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. *Antivir Ther*. 2004;9(5):713-719.
- Baillargeon J, Giordano TP, Rich JD, et al. Accessing antiretroviral therapy following release from prison. *JAMA*. 2009;301(8):848-857.
- Wohl DA, Golin CE, Knight K, et al. Randomized controlled trial of an intervention to maintain suppression of HIV viremia after prison release: the imPACT trial. *J Acquir Immune Defic Syndr*. 2017;75(1):81-90.
- Bradford JB, Coleman S, Cunningham W. HIV system navigation: an emerging model to improve HIV care access. *AIDS Patient Care STDS*. 2007;21(suppl 1):S49-S58.
- Higa DH, Marks G, Crepaz N, Liau A, Lyles CM. Interventions to improve retention in HIV primary care: a systematic review of U.S. studies. *Curr HIV/AIDS Rep*. 2012;9(4):313-325.

- Fowler T, Steakley C, Garcia AR, Kwok J, Bennett LM. Reducing disparities in the burden of cancer: the role of patient navigators. *PLoS Med*. 2006;3(7):e193.
- Metsch LR, Feaster DJ, Gooden L, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. *JAMA*. 2016;316(2):156-170.
- Okeke NL, Ostermann J, Thielman NM. Enhancing linkage and retention in HIV care: a review of interventions for highly resourced and resource-poor settings. *Curr HIV/AIDS Rep*. 2014;11(4):376-392.
- Tobias CR, Rajabion S, Franks J, et al. Peer knowledge and roles in supporting access to care and treatment. *J Community Health*. 2010;35(6):609-617.
- Kulkarni SP. The LAC HIV epidemic and TLC+ response presentation to LAC Board of Supervisors. Los Angeles County Department of Public Health Division of HIV and STD Programs; June 5, 2012. <http://publichealth.lacounty.gov/dhsp/Reports/HIV/TLCBrief4-12.pdf>. Accessed January 16, 2018.
- Malek M, Bazazi AR, Cox G, et al. Implementing opt-out programs at Los Angeles county jail: a gateway to novel research and interventions. *J Correct Health Care*. 2011;17(1):69-76.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. *Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents*. Washington, DC: Department of Health and Human Services; 2011.
- Gifford AL, Sengupta S. Self-management health education for chronic HIV infection. *AIDS Care*. 1999;11(1):115-130.
- Bandura A. *Self-efficacy: The Exercise of Control*. New York, NY: W.H. Freeman; 1997.
- Huynh AK, Kinsler JJ, Cunningham WE, Sayles JN. The role of mental health in mediating the relationship between social support and optimal ART adherence. *AIDS Care*. 2013;25(9):1179-1184.
- Kinsler JJ, Wong MD, Sayles JN, Davis C, Cunningham WE. The effect of perceived stigma from a health care provider on access to care among a low-income HIV-positive population. *AIDS Patient Care STDS*. 2007;21(8):584-592.
- Sayles JN, Wong MD, Kinsler JJ, Martins D, Cunningham WE. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. *J Gen Intern Med*. 2009;24(10):1101-1108.
- Schuster MA, Collins R, Cunningham WE, et al. Perceived discrimination in clinical care in a nationally representative sample of HIV-infected adults receiving health care. *J Gen Intern Med*. 2005;20(9):807-813.
- Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States: HCSUS Consortium: HIV cost and services utilization study. *Health Serv Res*. 2000;35(2):389-416.
- Cunningham WE, Hays RD, Williams KW, et al. Access to medical care and health-related quality of

- life for low-income persons with symptomatic human immunodeficiency virus. *Med Care*. 1995;33(7):739-754.
32. Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. *Med Care*. 1999;37(12):1270-1281.
33. Casewatch Millennium [computer program]. Los Angeles, California: Automated Case Management Systems, Inc; 1987.
34. Midanik LT, Hines AM, Barrett DC, Paul JP, Crosby GM, Stall RD. Self-reports of alcohol use, drug use and sexual behavior: expanding the timeline follow-back technique. *J Stud Alcohol*. 1998;59(6):681-689.
35. Ware J Jr, Kosinski M, Keller SDA. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. *Med Care*. 1996;34(3):220-233.
36. Weiss RE. *Modeling Longitudinal Data*. New York, NY: Springer; 2005.
37. Ning Li, Elashoff DA, Robbins WA, Lin Xun. A hierarchical zero-inflated log-normal model for skewed responses. *Stat Methods Med Res*. 2011;20(3):175-189.
38. Giordano TP, Cully J, Amico KR, et al. A randomized trial to test a peer mentor intervention to improve outcomes in persons hospitalized with HIV infection. *Clin Infect Dis*. 2016;63(5):678-686.
39. Stitzer M, Matheson T, Cunningham C, et al. Enhancing patient navigation to improve intervention session attendance and viral load suppression of persons with HIV and substance use: a secondary post hoc analysis of the Project HOPE study. *Addict Sci Clin Pract*. 2017;12(1):16.
40. Wilson IB, Bangsberg DR, Shen J, et al; Multisite Adherence Collaboration on HIV 14 Investigators. Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the multisite adherence collaboration on HIV 14 study. *J Acquir Immune Defic Syndr*. 2013;64(5):448-454.
41. Iroh PA, Mayo H, Nijhawan AE. The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis. *Am J Public Health*. 2015;105(7):e5-e16.
42. Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. *HIV Clin Trials*. 2007;8(4):205-212.
43. Cohen MS, Chen YQ, McCauley M, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011;365(6):493-505.
44. Hall HI, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. *AIDS*. 2012;26(7):893-896.
45. Coviello DM, Zanis DA, Wesnoski SA, Alterman AI. The effectiveness of outreach case management in re-enrolling discharged methadone patients. *Drug Alcohol Depend*. 2006;85(1):56-65.
46. Sorensen JL, Masson CL, Delucchi K, et al. Randomized trial of drug abuse treatment-linkage strategies. *J Consult Clin Psychol*. 2005;73(6):1026-1035.
47. Rajabiun S, Mallinson RK, McCoy K, et al. "Getting me back on track": the role of outreach interventions in engaging and retaining people living with HIV/AIDS in medical care. *AIDS Patient Care STDS*. 2007;21(S1)(suppl 1):S20-S29.
48. Liau A, Crepaz N, Lyles CM, et al; HIV/AIDS Prevention Research Synthesis (PRS) Team. Interventions to promote linkage to and utilization of HIV medical care among HIV-diagnosed persons: a qualitative systematic review, 1996-2011. *AIDS Behav*. 2013;17(6):1941-1962.
49. Gardner LI, Metsch LR, Anderson-Mahoney P, et al; Antiretroviral Treatment and Access Study Group. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. *AIDS*. 2005;19(4):423-431.
50. Molitor F, Waltermeyer J, Mendoza M, et al. Locating and linking to medical care HIV-positive persons without a history of care: findings from the California Bridge Project. *AIDS Care*. 2006;18(5):456-459.
51. Gardner LI, Giordano TP, Marks G, et al; Retention in Care Study Group. Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics. *Clin Infect Dis*. 2014;59(5):725-734.
52. Bracken N, Hilliard C, McCuller WJ, Harawa NT. Facilitators of HIV medical care engagement among former prisoners. *AIDS Educ Prev*. 2015;27(6):566-583.
53. Katz MH, Cunningham WE, Fleishman JA, et al. Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons. *Ann Intern Med*. 2001;135(8, pt 1):557-565.
54. Cunningham WE, Sohler NL, Tobias C, et al. Health services utilization for people with HIV infection: comparison of a population targeted for outreach with the U.S. population in care. *Med Care*. 2006;44(11):1038-1047.
55. Simoni JM, Huh D, Wang Y, et al. The validity of self-reported medication adherence as an outcome in clinical trials of adherence-promotion interventions: findings from the MACH14 study. *AIDS Behav*. 2014;18(12):2285-2290.
56. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. *HIV Clin Trials*. 2004;5(2):74-79.
57. Wagner GJ, Rabkin JG. Measuring medication adherence: are missed doses reported more accurately than perfect adherence? *AIDS Care*. 2000;12(4):405-408.
58. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. *Clin Infect Dis*. 2006;43(7):939-941.
59. Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. *Ann Pharmacother*. 2011;45(3):372-379.
60. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. *J Acquir Immune Defic Syndr*. 2007;45(1):4-8.